This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biogen Idec To Present New Clinical Data From Its Robust Neurology Portfolio At AAN Annual Meeting

Stocks in this article: BIIB

Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66 th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases.

“For more than 20 years, Biogen Idec has been dedicated to improving the lives of people with MS,” said Alfred Sandrock, M.D., Ph.D., group senior vice president, and chief medical officer at Biogen Idec. “We have a broad portfolio and pipeline of innovative MS medicines, we perform important research that continues to advance our understanding of this disease, and we provide meaningful support services for people living with MS. The breadth of data we are presenting at AAN reinforces our enduring commitment to reducing the impact of MS and other serious neurodegenerative diseases.”

As part of its ongoing commitment to further understand the underlying causes of neurological disease, Biogen Idec is presenting new data to help patients and their healthcare providers make optimal treatment decisions and improve patient outcomes. In addition, data at AAN will include results from studies of its currently marketed products, TECFIDERA ® (dimethyl fumarate), TYSABRI ® (natalizumab), AVONEX ® (interferon beta-1a) and FAMPYRA ® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033).

In addition to data presented at the meeting, Biogen Idec will support the American Brain Foundation’s 2014 Brain Health Fair. On Saturday, April 26 Biogen Idec will help sponsor a free, day-long family event that aims to connect thousands of patients, families and caregivers affected by neurological disease. The Brain Health Fair will offer scientific presentations and discussions, educational activities, and a film festival competition that aims to increase public awareness and understanding of neurological disease. Registration is free at BrainHealthFair.com.

1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs